Research Progress of H[sub.2]S Donors Conjugate Drugs Based on ADTOH

H[sub.2] S is an endogenous gas signaling molecule and its multiple biological effects have been demonstrated. The abnormal level of H[sub.2] S is closely related to the occurrence and development of many diseases, and H[sub.2] S donors has important pharmacological implications. In recent years, H[...

Full description

Saved in:
Bibliographic Details
Published in:Molecules (Basel, Switzerland) Switzerland), 2022-12, Vol.28 (1)
Main Authors: Wen, Shuai, Cao, Changchang, Ge, Jianwen, Yang, Wenzhe, Wang, Yan, Mou, Yi
Format: Article
Language:English
Subjects:
Chemical properties
Drug discovery
Health aspects
Hydrogen sulfide
Organosulfur compounds
Pharmaceutical research
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:H[sub.2] S is an endogenous gas signaling molecule and its multiple biological effects have been demonstrated. The abnormal level of H[sub.2] S is closely related to the occurrence and development of many diseases, and H[sub.2] S donors has important pharmacological implications. In recent years, H[sub.2] S donors represented by ADTOH (5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione) are often used to synthesize new ‘conjugate’ compounds that can release H[sub.2] S and parent drugs. These hybrids retain the pharmacological activity of the parent drugs and H[sub.2] S and have a synergistic effect. ADTOH and parent drug hybrids have become one of the important strategies for the development of H[sub.2] S donor conjugate drugs. This review summarizes molecular hybrids between ADTOH and clinical drugs to provide new ideas for the study of H[sub.2] S donor drug design.
ISSN:1420-3049
1420-3049
DOI:10.3390/molecules28010331